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Introduction 
Demyelinating forms of Charcot-Marie-Tooth (CMT) result from mutations in a 
number of genes, the majority of which show an autosomal dominant pattern of 
inheritance [1]. Recessive patterns of inheritance are less common. We report a case 
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of demyelinating CMT resulting from compound heterozygous mutation in the FGD4 
gene. 
 
Clinical presentation 
 
A 61-year-old Caucasian woman progressive unsteadiness since age 36. At age 35, 
she was diagnosed as having Friedreichs ataxia. She had not been followed-up since 
then. The patient recalled having dexterity difficulties and frequent falls since the 
age of 8. She had multiple foot surgeries. She had a normal birth and normal 
milestones. 
 
There was no relevant family history. The patient had two sisters, who both died of 
cancer. The patient reported that her mother had clawed toes but walked normally 
in her 90s. Past medical history included arterial hypertension and a hip 
replacement at the age of 52. The patient was smoking and was not drinking alcohol 
excessively. 
 
Examination revealed kyphoscoliosis. Neurological examination showed normal 
cranial nerves, apart from broken pursuit eye movements. There was no nystagmus. 
There was mild finger to nose ataxia and more prominent heel to shin and gait 
ataxia. She could walk using bilateral support. She had mild pes cavus and deformed 
feet. There was bilateral foot drop. Her right leg was weaker compared to the left, 
following the hip replacement. She had distal weakness (MRC 4) in both hands. She 
was areflexic. 
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She had severe sensory loss (pinprick and proprioception) in both arms up to the 
elbows and both legs up to the knees. Vibration sensation was absent in the limbs. 
Rombergs sign was positive.  
 
Routine blood tests, vitamin B12, folate and immunology testing were normal or 
negative. She had increased thyroglobulin and thyroid peroxidase antibodies, but 
thyroid function testing was normal.  
 
MRI of the brain was unremarkable.  
 
Nerve conduction studies showed absent sensory responses. Motor conduction 
studies showed reduced amplitudes (0.5  1.2mV) and severely reduced velocities 
(8-14 m/sec).  
 
Genetic screening for the chromosome 17 duplication and for mutations in PMP22, 
MPZ, NEFL, GDAP1, GJB1, EGR2 and the common mitochondrial mutations (MELAS, 
MERRF and NARP) were all negative. Next generation sequencing analysis of a panel 
of 14 genes (GJB1, EGR2, FGD4, FIG4, GADP1, LITAF, MPZ, MTMR2, NDRG1, NEFL, 
PMP22, PRX, SBF2, SH3TC2) implicated in CMT1 revealed two heterozygous likely 
pathogenic variants in FGD4: c.[1192-48_1233del];[1304_1305delinsAA] 
p.{(?);(Arg435Gln)]. Neither mutation has been previously reported on public normal 
variant databases (dbSNP, NHLBI, exome variant server and ExAC). The c.1192-
48_1233del p.(?) mutation is a 90 bp deletion encompassing the intron 9 / exon 10 
boundary and is predicted to result in a truncated and/or frameshifted transcript 
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and a loss of function. The c.1394_1305delinsAA p.(Arg435Gln) missense mutation 
occurs at a highly conserved amino acid within the plekstrin homology domain, a 
domain in which a pathogenic recessive missense mutation has previously been 
reported (p.Arg442His PMID 22734899). As this missense mutation resides within 
the 90 bp deletion in the first mutation, we were able to confirm autosomal 
recessive inheritance by Sanger sequencing showing that these two mutations were 
present on separate alleles despite not having her parents DNA available.  
 
Discussion 
CMT type 4 is the term commonly used to describe autosomal recessive CMT1 
(ARCMT1) cases although some also classify the autosomal recessive CMT2 ARCMT2 
cases as CMT4 [2]. CMT type 4H is characterized by an early onset (up to the age of 
10 years) demyelinating neuropathy, with slow progression and scoliosis [3]. The 
diagnosis is established by the presence of biallelic FGD4 pathogenic variants. 
 
In the case described here there was no clear family history of neuropathy. The 
presence of kyphoscoliosis, however, in combination with the very severe 
neuropathy as indicated by the NCS pointed towards CMT4. 
 
Sensory ataxia when severe can be difficult to distinguish from cerebellar ataxia. 
Nerve conduction studies in such patients are essential in deciding which gene 
panels to pursue based on the type and severity of the neuropathy. This case also 
illustrates the need for up to date review of patients labeled as having a particular 
genetic disease prior to the availability of genetic testing for confirmation. 
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